Sign in
CompletedNo phase

DMID 21-0041; Influenza CVD 59000

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore and College Park, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
34 people enrolled
Started
20 Feb 2023
Ended
17 Apr 2024
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Personal Protective Equipment (PPE) - Under High Air Hygiene
  • No Intervention - Under High Air Hygiene
  • Personal Protective Equipment (PPE) - Under Low Air Hygiene
  • No Intervention - Under Low Air Hygiene
Record updated
26 August 2025

Who can take part

Age
18 years to 59 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Provides written informed consent, able to comply with the planned study procedures, available for between 2 and 5 days stay in the research quarantine unit for the CHIVITT, and have the ability to attend the scheduled follow-up visits
  • Subjects must be able to comprehend the study requirements, as evidenced by a score of ≥70% or better on the comprehension assessment (two attempts permitted)
  • Males and non-pregnant, non-breastfeeding females1 aged ≥18 and ≤59 years of age, at time of initial consent; *Pregnancy and breastfeeding status to be determined by self-report
  • Laboratory-confirmed influenza infection within the past 48 hours at time of entry into the exposure event; *A rapid antigen test in the setting of known local influenza activity and with symptoms suggestive of influenza at that time is acceptable
  • Within the past 48 hours at time of entry into the exposure event, onset of influenza-like illness, as defined as fever (measured oral temperature of ≥100.2°F or self-reported fever in the absence of a measured temperature) AND cough or sore throat, or onset of less specific symptoms with a positive molecular test for influenza virus infection
  • No self-reported or known history of alcohol or drug abuse within the past two years and no illicit drug use within the last 30 days
  • Do not have clinically significant medical, psychiatric, and chronic or intermittent health conditions including those listed in Exclusion Criteria
  • Does not have an ongoing symptomatic condition for which subject has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan; *e.g., ongoing and debilitating fatigue without a diagnosis for the symptom
  • Agrees to the collection of specimens for secondary research
  • Enrolled in the Recipient Protocol (University of Maryland, Baltimore Institutional Review Board HP-97730)
  • Provides written informed consent, able to comply with the planned study procedures, be available for an up to ~14-day stay for the CHIVITT and have the ability to attend the scheduled follow-up visits
  • Subjects must be able to comprehend the study requirements, as evidenced by a score of ≥70% or better on the comprehension assessment (two attempts permitted)
  • No change in smoker status, alcoholism, or illicit drug use status, as compared from their responses collected during screening (EMIT-2 Recipient Protocol). (Prescribed stimulants for the treatment of attention deficit hyperactivity disorder [ADHD] and cannabinoids use do not constitute exclusionary criteria)
  • No significant change (for the worse) in general health history or in concomitant medication use, as compared from their responses collected during screening (EMIT-2 Recipient Protocol)
  • Agree not to meet with other participants (recipients or donors) outside of the programmed exposure events during the course of their participation in the CHIVITT

Who cannot take part

  • Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness7
  • History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis
  • Participating in any other interventional clinical research study that has a scheduled intervention 30 days prior to the CHIVITT or 30 after discharge from the research quarantine unit
  • Has an ongoing symptomatic condition1 for which the subject has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan; *e.g., ongoing chronic fatigue without a diagnosis for symptom
  • History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis
  • Presence of self-reported or medically documented significant medical or psychiatric condition(s)5; *Significant medical or psychiatric conditions include but are not limited to:; Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma, cystic fibrosis) requiring daily medications6 currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years
  • Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short-acting beta agonists, theophylline, ipratropium, biologics; Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult; Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis); Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible; An autoimmune disease. f. An immunodeficiency of any cause. g. A blood disorder (e.g., sickle cell disease) h. Endocrine disorders (e.g., diabetes) i. Liver, kidney, metabolic disorders j. BMI ≥40 kg/m2 k. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the transmission study over the next several days
  • Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 12-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted
  • Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to acetaminophen/paracetamol)
  • Presence of co-infection with SARS-CoV-2, as detected via a multiplex nucleic acid amplification test (e.g., Biofire)
  • Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the subject or the study objectives; For Recipients:
  • Presence of infection with influenza, SARS-CoV-2, or other respiratory pathogens detected via a multiplex nucleic acid amplification test (e.g., Biofire) at admission to the hotel quarantine facility
  • Within the past 72 hours, presence of influenza-like illness, as defined as fever of ≥100.2°F AND cough or sore throat, in the absence of an alternative cause
  • Self-reported or known history of alcohol or drug abuse in the past two years and no illicit drug use within the last 30 days
  • Presence of self-reported or medically documented significant medical or psychiatric condition(s)2; *Significant medical or psychiatric conditions include but are not limited to:; Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma, cystic fibrosis) requiring daily medications* currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years; *Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short-acting beta agonists, theophylline, ipratropium, biologics; Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult; Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis); Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible; An autoimmune disease; An immunodeficiency of any cause; A blood disorder (e.g., sickle cell disease); Endocrine disorders (e.g., diabetes); Liver, kidney, metabolic disorders; BMI ≥40 kg/m2; Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the screening or future transmission studies
  • Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness3; *Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 12-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted
  • Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to oseltamivir, baloxavir, acetaminophen/paracetamol)
  • Female of childbearing potential who is breastfeeding or has positive urine pregnancy test upon admission to the hotel quarantine unit
  • Is a habitual smoker8 of tobacco, marijuana, or e-cigarettes per self-report; Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion
  • Female of childbearing potential who has a positive urine pregnancy test within 24 hours of admission to the hotel quarantine unit or is breastfeeding or planning to become pregnant within 2 months after entry into a CHIVITT
  • Receipt of any blood products within the past 2 months
  • Does not agree to provide permission for secondary research use of extra samples collected and stored specimens
  • Habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. (Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.)

Other criteria

  • For Donors:

Where in United States

  • University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global HealthBaltimore, United States
  • University of Maryland, College Park School of Public HealthCollege Park, United States

About the trial

What the trial wants to find out

The primary objective of EMIT-2 is to use a randomized controlled trial (RCT) design to implement interventions which are known to reduce inhalation (airborne) transmission, so that the contribution of transmission by route of aerosols for influenza may be identified.

The 3 groups in the trial

  • DonorsOther group

    Donors are persons naturally infected with influenza.

    Treatment: No Intervention - Under High Air Hygiene and No Intervention - Under Low Air Hygiene

  • Intervention RecipientsTreatment being tested

    Intervention recipients are participants who do not have influenza and will use personal protective equipment.

    Treatment: Personal Protective Equipment (PPE) - Under High Air Hygiene and Personal Protective Equipment (PPE) - Under Low Air Hygiene

  • Control RecipientsNo study treatment, for comparison

    Control recipients are participants who do not have influenza and will not be using personal protective equipment.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating Modes of Influenza Transmission Through the Conduct of Controlled Human Influenza Virus Infection Transmission Trials (CHIVITTs)
Record updated
26 August 2025